Peter Chockley

First corresponding paper is out! Thank you to @Jorge88382322 and @GiedreKrenciute for the beautiful imaging and brain tumor models, Lindsay Talbot for the stunning HALO assay, and @Kyttaro_Therapy for the mentorship and support. All made possible by @StJude and @StJudeResearch

Congrats to Dept. of Molecular Medicine and Therapeutics (MMT), #PIIO member @PeterChockley on being featured in the @AACR Cancer Immunology (CIMM) Junior Investigator Profile! His lab is advancing next-generation #CAR designs & synthetic receptor engineering to enhance #NKcell & #Tcell #antitumor activity. linkedin.com/feed/update/ur…

The Sim lab has been hard at work and we’re proud to present our first paper. We developed new methods to study peptide:KIR interactions. Congratulations to star postdoc Tanusya Murali who led the project. biorxiv.org/content/10.648…

🔬 Join us for a live webinar: “Cell Avidity Uncovers Novel KIR:HLA Binding — Predicting Patient Survival Post Stem Cell Transplant” with Dr. @PeterChockley 📅 November 19, 2025 | 4PM (EST) 🔗 Register now: lumicks.com/event/webinar/… #CellTherapy #NKcells #KIRHLA #StemCellTransplant #ImmunoOncology

@PGTimmune Congrats, Paul!

fredhutch.org/en/news/center…"

After many rewarding years at @StJudeResearch surrounded by exceptional colleagues & groundbreaking science, I’m delighted to join @fredhutch to push boundaries in viral & cancer immunology. Grateful to St. Jude and looking forward to what’s next at FH! More about the move below

Esther Obeng leads a research group focused on myelodysplastic syndromes (MDS) @EmoryMedicine. @JExpMed spoke with Esther about her career, how her patients inform her research, and more #WomenInSTEM rupress.org/jem/article/22…

@CarlKoschmann @chadtough @MottChildren @UMRogelCancer @umichmedicine Which design/target y’all going with??? Super exciting!

Excited for City of Hope Car-T to now be open at U of M for children with DMG/DIPG! This wouldnt be possible without @chadtough support! First Car-T for brain tumors in the Midwest!! michiganmedicine.org/health-lab/new… @MottChildren @chadtough @UMRogelCancer @umichmedicine

The Foltz lab is growing! If you are interested in working on improving NK cell therapies for cancer, consider applying at: wustl.wd1.myworkdayjobs.com/en-US/External… or reaching out to us at jfoltzlab.org! @WashUDeptMed @WUSTLImmuno @SitemanCenter

I’m hiring a sr. bioinformatics research scientist in integrative analysis to perform data analysis and visualization, statistical analysis, experimental design, database development, mathematical modeling, and novel method development. Join the team. tinyurl.com/39fz6cwy

Come join my lab as a sr. scientist focused on applied integrative biology to develop and implement novel technical approaches for assaying single cell dynamics, high throughput functional screening, and high parameter molecular phenotyping. tinyurl.com/3466kx8u #NowHiring

It’s a great day when years of research comes out to the world! Great work from a great team! @StJudeResearch stjude.org/media-resource…

@Jeff_Mold Would love to see their cell “definitions”…

RNAseq is commonly performed. We compared N=30 wild-type Bl6 mice to an N=30 heterozygotic knockout with a phenotype, and then downsized. We found you need at least an N= 8-12 to avoid a >50% false positive rate. A 2nd line confirmed the finding. biorxiv.org/content/10.110…

Congrats to @FoltzPhd @Jenn__Tran and the whole team! New insights into the molecular program of memory-like #NKcell @WUSTLmed @WUSTLImmuno @SitemanCenter science.org/doi/10.1126/sc…

@sidichen @YaleGenetics @YaleMed @YaleWestCampus @YaleCancer @YaleData Great to see the final product!

Our first in vivo primary NK screen that discovered new NK cellular checkpoints. Kudos for team for their 5 years of work. nature.com/articles/s4158… @YaleGenetics @YaleMed @YaleWestCampus @YaleCancer @YaleData

In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy go.nature.com/4cfyac2

@jkagan1 Totally agree. 6week vs 8week old mouse can dictate tumor growth or rejection. I rarely accept a 5 week old mouse study as mildly relevant scientifically.

So much of our knowledge of immunity is based on studies in young mice. Yet we know that the immune system changes as we age. How many rules of immunity are age-dependent? Are any rules age agnostic?

@KlebanoffLab @parkerici @MSKCancerCenter Nice story! Any solid tumor plans noting your 2019 JCI paper?

🚨Pre-print alert: Here, we show that CAR-T *and* CAR-NK persistence is negatively self-regulated through activation dependent FAS ligand expression. Further highlights FAS as an actionable molecule to enhance cell therapies. @parkerici @MSKCancerCenter biorxiv.org/content/10.110…

Join us for The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) at St. Jude in June 2024. stjude.org/education-trai… @StJude @StJudeResearch @ASTCT @ThePTCTC

Full resolution HLA and KIR genes annotation for human genome assemblies biorxiv.org/cgi/content/sh… #biorxiv_immuno

Proud of Matt Bell who published his graduate work on leucine zipper cytokine receptors today in BME! nature.com/articles/s4155…